Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Таргетные препараты: рациональный выбор первой линии лекарственной терапии диссеминированного колоректального рака
Таргетные препараты: рациональный выбор первой линии лекарственной терапии диссеминированного колоректального рака
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Moosmann N, Heinemann V. Cetuximab in the treatment of metastatic colorectal cancer. Exp Opin Biol Ther 2007; 7 (2): 243–56.
2. Lenz H-J. Cetuximab in the management of colorectal cancer. Biol Targ Ther 2007; 1 (2): 77–91.
3. Van Cutsem E, Nowacki M et al. Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first-line treatment of pts with metastatic colorectal cancer. CRYSTAL trial. ASCO 2007; abstr. 4000.
4. Bokemeyer C et al. ASCO 2007; abstract No. 4035.
5. Van Cutsem E et al. ASCO GI Congress 2010; abstr 281.
6. Bokemeyer C et al. ASCO GI Congress 2010; abstr 428.
7. Koehne C et al. ASCO GI Congress 2010; abstr 406.
8. Siena S, Cassidy S, Tabernero R et al. ASCO-GI 2010; A 283.
9. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60–5.
10. Kabbinavar F, Schulz J, McCleod M et al. Bevacizumab (Avastin), a monoclonal antibody to vascular endothelial growth factor, prolongs progression free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. Proc Am Soc Clin Oncol 2004; 23: 249, abstr 3516.
11. Hurwitz HI, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.
12. Goldberg RM, Sargent DJ, Morton RF et al. N9741:FOLFOX (oxaliplatin(Oxal)/5-fluoroeracil (5-FU)/leucovorin (LV) or reduce dose R-IFL (CPT-11+5-FU/LV) in advanced colorectal cancer (CRC): final efficacy data from intergroup study. Proc Am Soc Clin Oncol 2004; 23: abstr. 3621.
13. Saltz L et al. JCO 2008; 26: 2013–9.
14. Saltz LB. ASCO GI 2007; аbstr No. 238.
15. Hecht JR et al. JCO 2008; 27: 1–14.
16. Tol J et al. NEJM 2009; 360: 563–72.
17. Nordlinger B, Van Cutsem E, Rougier P et al., on behalf of European Colorectal Metastases Treatment Group Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group (ECMTG). Eur J Cancer 2007; 43: 2037–45.
18. Folprecht G et al. ASCO-GI 2009; аbstr 296.
19. Folprecht G et al. Published online Nov 25, 2009; DOI:10.1016/S1470-2045(09)70330-4.
20. Garufi C et al. ASCO GI 2008; аbstr No. 367.
21. Samalin E et al. WCGIC 2009; A PD-0011.
22. Barroso S et al. JCO 2009; 27 (Suppl. 15):аbstr e15013.
23. Rivera F et al. ECCO-ESMO 2009; аbstr 4004.
24. Ocvirk J et al. WCGIC 2009; аbstr No: PD-0021.
25. Acta Oncologica, 2010.
26. Tabernero J et al. AACR 2007; abstr LB-352.
27. Pfeiffer P et al. ASCO GI 2007; abstr No. 305.
2. Lenz H-J. Cetuximab in the management of colorectal cancer. Biol Targ Ther 2007; 1 (2): 77–91.
3. Van Cutsem E, Nowacki M et al. Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first-line treatment of pts with metastatic colorectal cancer. CRYSTAL trial. ASCO 2007; abstr. 4000.
4. Bokemeyer C et al. ASCO 2007; abstract No. 4035.
5. Van Cutsem E et al. ASCO GI Congress 2010; abstr 281.
6. Bokemeyer C et al. ASCO GI Congress 2010; abstr 428.
7. Koehne C et al. ASCO GI Congress 2010; abstr 406.
8. Siena S, Cassidy S, Tabernero R et al. ASCO-GI 2010; A 283.
9. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60–5.
10. Kabbinavar F, Schulz J, McCleod M et al. Bevacizumab (Avastin), a monoclonal antibody to vascular endothelial growth factor, prolongs progression free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. Proc Am Soc Clin Oncol 2004; 23: 249, abstr 3516.
11. Hurwitz HI, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.
12. Goldberg RM, Sargent DJ, Morton RF et al. N9741:FOLFOX (oxaliplatin(Oxal)/5-fluoroeracil (5-FU)/leucovorin (LV) or reduce dose R-IFL (CPT-11+5-FU/LV) in advanced colorectal cancer (CRC): final efficacy data from intergroup study. Proc Am Soc Clin Oncol 2004; 23: abstr. 3621.
13. Saltz L et al. JCO 2008; 26: 2013–9.
14. Saltz LB. ASCO GI 2007; аbstr No. 238.
15. Hecht JR et al. JCO 2008; 27: 1–14.
16. Tol J et al. NEJM 2009; 360: 563–72.
17. Nordlinger B, Van Cutsem E, Rougier P et al., on behalf of European Colorectal Metastases Treatment Group Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group (ECMTG). Eur J Cancer 2007; 43: 2037–45.
18. Folprecht G et al. ASCO-GI 2009; аbstr 296.
19. Folprecht G et al. Published online Nov 25, 2009; DOI:10.1016/S1470-2045(09)70330-4.
20. Garufi C et al. ASCO GI 2008; аbstr No. 367.
21. Samalin E et al. WCGIC 2009; A PD-0011.
22. Barroso S et al. JCO 2009; 27 (Suppl. 15):аbstr e15013.
23. Rivera F et al. ECCO-ESMO 2009; аbstr 4004.
24. Ocvirk J et al. WCGIC 2009; аbstr No: PD-0021.
25. Acta Oncologica, 2010.
26. Tabernero J et al. AACR 2007; abstr LB-352.
27. Pfeiffer P et al. ASCO GI 2007; abstr No. 305.
Авторы
Н.С.Бесова
РОНЦ им. Н.Н.Блохина РАМН, Москва
РОНЦ им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.